A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer

A case report

Won Jin Ho, Lisa Rooper, Sarah Sagorsky, Hyunseok Kang

Research output: Contribution to journalArticle

Abstract

Background: Human papillomavirus-related small cell carcinoma of the head and neck is an extremely rare, aggressive subtype with poor outcomes. Therapeutic options are limited and are largely adopted from small cell lung cancer treatment paradigms. Case presentation: This report describes a 69-year old male who was diagnosed of HPV-related oropharyngeal cancer with mixed small cell and squamous cell pathology which was clinically aggressive and progressed through multimodal platinum-based therapies. Upon manifestation of worsening metastatic disease, the patient was initiated on a combination of ipilimumab and nivolumab. Within 2 months of starting immunotherapy, a robust partial response was observed. During the treatment course, the patient developed immune-related adverse effects including new diabetes mellitus, colitis, and hypothyroidism. The disease-specific survival was 26 months. Conclusion: Combination immunotherapy may be an attractive option for HPV-related small cell head and neck cancers resistant to other treatment modalities and thus warrants further evaluation.

Original languageEnglish (US)
Article number33
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - May 9 2018

Fingerprint

Neoplasms
Immunotherapy
Oropharyngeal Neoplasms
Therapeutics
Small Cell Carcinoma
Small Cell Lung Carcinoma
Colitis
Head and Neck Neoplasms
Hypothyroidism
Platinum
Diabetes Mellitus
Neck
Epithelial Cells
Head
Pathology
Survival
ipilimumab
nivolumab

Keywords

  • HPV
  • Immunotherapy
  • Oropharyngeal
  • Small cell cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer : A case report. / Ho, Won Jin; Rooper, Lisa; Sagorsky, Sarah; Kang, Hyunseok.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 33, 09.05.2018.

Research output: Contribution to journalArticle

@article{b944399e38ac4b67a9c4eb1a0cf4e8dc,
title = "A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: A case report",
abstract = "Background: Human papillomavirus-related small cell carcinoma of the head and neck is an extremely rare, aggressive subtype with poor outcomes. Therapeutic options are limited and are largely adopted from small cell lung cancer treatment paradigms. Case presentation: This report describes a 69-year old male who was diagnosed of HPV-related oropharyngeal cancer with mixed small cell and squamous cell pathology which was clinically aggressive and progressed through multimodal platinum-based therapies. Upon manifestation of worsening metastatic disease, the patient was initiated on a combination of ipilimumab and nivolumab. Within 2 months of starting immunotherapy, a robust partial response was observed. During the treatment course, the patient developed immune-related adverse effects including new diabetes mellitus, colitis, and hypothyroidism. The disease-specific survival was 26 months. Conclusion: Combination immunotherapy may be an attractive option for HPV-related small cell head and neck cancers resistant to other treatment modalities and thus warrants further evaluation.",
keywords = "HPV, Immunotherapy, Oropharyngeal, Small cell cancer",
author = "Ho, {Won Jin} and Lisa Rooper and Sarah Sagorsky and Hyunseok Kang",
year = "2018",
month = "5",
day = "9",
doi = "10.1186/s40425-018-0348-4",
language = "English (US)",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer

T2 - A case report

AU - Ho, Won Jin

AU - Rooper, Lisa

AU - Sagorsky, Sarah

AU - Kang, Hyunseok

PY - 2018/5/9

Y1 - 2018/5/9

N2 - Background: Human papillomavirus-related small cell carcinoma of the head and neck is an extremely rare, aggressive subtype with poor outcomes. Therapeutic options are limited and are largely adopted from small cell lung cancer treatment paradigms. Case presentation: This report describes a 69-year old male who was diagnosed of HPV-related oropharyngeal cancer with mixed small cell and squamous cell pathology which was clinically aggressive and progressed through multimodal platinum-based therapies. Upon manifestation of worsening metastatic disease, the patient was initiated on a combination of ipilimumab and nivolumab. Within 2 months of starting immunotherapy, a robust partial response was observed. During the treatment course, the patient developed immune-related adverse effects including new diabetes mellitus, colitis, and hypothyroidism. The disease-specific survival was 26 months. Conclusion: Combination immunotherapy may be an attractive option for HPV-related small cell head and neck cancers resistant to other treatment modalities and thus warrants further evaluation.

AB - Background: Human papillomavirus-related small cell carcinoma of the head and neck is an extremely rare, aggressive subtype with poor outcomes. Therapeutic options are limited and are largely adopted from small cell lung cancer treatment paradigms. Case presentation: This report describes a 69-year old male who was diagnosed of HPV-related oropharyngeal cancer with mixed small cell and squamous cell pathology which was clinically aggressive and progressed through multimodal platinum-based therapies. Upon manifestation of worsening metastatic disease, the patient was initiated on a combination of ipilimumab and nivolumab. Within 2 months of starting immunotherapy, a robust partial response was observed. During the treatment course, the patient developed immune-related adverse effects including new diabetes mellitus, colitis, and hypothyroidism. The disease-specific survival was 26 months. Conclusion: Combination immunotherapy may be an attractive option for HPV-related small cell head and neck cancers resistant to other treatment modalities and thus warrants further evaluation.

KW - HPV

KW - Immunotherapy

KW - Oropharyngeal

KW - Small cell cancer

UR - http://www.scopus.com/inward/record.url?scp=85046655696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046655696&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0348-4

DO - 10.1186/s40425-018-0348-4

M3 - Article

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 33

ER -